RxDoctor Payments Data

Evan Levine, DO

Cardiovascular Disease · White Plains, NYNPI 1326482555

Payments from drug & device makers

$80,297in general payments, 2019–2025

Across 115 payments — averaging $698.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$79K
  • Amgen$770
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$215
  • Pfizer$198
  • E.r. Squibb & Sons, L.L.C.$140
  • Lilly USA, LLC$73
  • plus $367 from 10 others

What the payments were for

  • Speaking & faculty fees$71,38689%
  • Travel & lodging$5,8007%
  • Food & beverage$3,0784%
  • Education$320%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$80,297 in reported general payments places this provider in the 90th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$365,298
Medicare patients
2,857
Services billed
5,837

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban331$409,511
EntrestoSacubitril/Valsartan89$129,525
Repatha SureclickEvolocumab59$69,357
XareltoRivaroxaban37$54,717
JardianceEmpagliflozin25$41,336
WegovySemaglutide22$28,933
BrilintaTicagrelor12$15,585
Metoprolol Succinate554$8,085
Atorvastatin Calcium528$6,392
Rosuvastatin Calcium227$4,376
Valsartan160$4,166
Ranolazine ErRanolazine17$3,575
Ezetimibe84$2,713
Labetalol Hcl85$2,685
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide99$2,317

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$198$409,511331 claims
NovartisEntresto$44$129,52589 claims
Johnson & JohnsonXarelto$16$54,71737 claims
Boehringer IngelheimJardiance$12$41,33625 claims
Novo NordiskWegovy$78,534$28,93322 claims
AstraZenecaBrilinta$33$15,58512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in White Plains

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →